This slide show looks at patient access to oncology agents both in the United States and abroad, and examines barriers and other constraints preventing new treatments from getting into the hands of patients.
This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
This slide show features some of the top highlights from the 2015 Society of Gynecologic Oncology Annual Meeting, including a vaccine trial in ovarian cancer and a possible biomarker in advanced cervical cancer.
Accumulating evidence suggests that aspirin could decrease the risk of a cancer diagnosis or the chance of death from commonly diagnosed cancers. However, studies and clinical trials have been mixed, and do the benefits outweigh the risks of gastrointestinal bleeding and peptic ulcers?
Ahead of the World Tobacco Congress, Dr. Alan Blum and Cancer Network have partnered to assemble a four-part slideshow series addressing the history of America’s smoking pandemic. Part 1 examines the early evidence linking smoking with cancer.
This slide show includes some of the top highlights from the 2015 ASCO Genitourinary Cancers Symposium, including a study that examined the risk of aggressive prostate cancer in testicular cancer survivors and more.
This slide show highlights recent studies that examined coffee consumption as it relates to cancer risk, including melanoma, breast and liver cancers, and more.
This slide show includes some of the highlights from the 2015 ASCO Gastrointestinal Cancers Symposium, including a study that linked vitamin D levels to colorectal cancer outcomes, positive results in pancreatic cancer with a new targeted agent, and more.
In this slide show we present some of the top cancer stories of 2014, including a newly discovered gene that confers a high-risk of breast cancer and the impressive survival improvement with the addition of docetaxel to ADT in newly diagnosed metastatic prostate cancer.